Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Deere & Company (DE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Deere & Company — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $222.08 (market cap $29.60B), while Deere & Company trades at $619.99 (market cap $166.81B). The key difference: Deere & Company is far larger — about 5.6× Alnylam Pharmaceuticals, Inc.'s market cap, and Deere & Company pays a 1.05% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | DE | |
|---|---|---|
Market Cap | $29.60B | $166.81B |
Sector | Health | Industrials |
52-Week High | $491.22 | $662.49 |
52-Week Low | $205.48 | $439.11 |
Enterprise Value | $27.56B | $221.63B |
Dividend Yield | — | 1.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.
The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.
Deere & Company (DE) trades at $609.28, down 1.86% on the day, amid mixed signals. The stock shows a bullish technical trend with strong moving averages, but oscillators are neutral. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $6.55 surpassing the $5.70 estimate. Revenue declined to $44.67B in 2025, with net income margin at 10.33%. Analyst consensus is a Moderate Buy, with a price target of $669.79, implying potential upside. The company maintains a solid balance sheet with $8.48B in cash, though debt levels remain elevated.
The outlook for DE is cautiously optimistic, driven by earnings beats and analyst confidence, but tempered by revenue declines and agricultural cycle risks. Investment opportunity lies in the valuation gap to the consensus target, while key risks include weak North American demand and margin pressure highlighted in recent industry reports. The stock's performance hinges on upcoming Q3 2026 earnings on August 20, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Deere & Company
Deere is the world's leading manufacturer of agricultural equipment, producing some of the most recognizable machines in the heavy machinery industry. The company is divided into four reportable segments: production and precision agriculture, small agriculture and turf, construction and forestry, and John Deere Capital. Its products are available through an extensive dealer network, which includes over 1,900 dealer locations in North America and approximately 3,700 locations globally. John Deere Capital provides retail financing for machinery to its customers, in addition to wholesale financing for dealers, which increases the likelihood of Deere product sales.
Read more on DE →
